2 Items on Genzyme Ireland FDA-483

FDA has released the form FDA-483 issued following a 1/9-1/17 inspection at the Genzyme Ireland drug manufacturing facility in Waterford, Ireland. The two inspection observations were:

  • failure to establish procedures, processes, and testing designed to prevent microbial contamination of the drug product purporting to be sterile; and
  • failure to adequately maintain redacted systems in support of drug manufacture.

Read more